Health & Wellness

Atlantic Health System Cancer Care First in World to Begin Clinical Trial of Novel Virus-Based Immunotherapy for Late-Stage Melanoma; First Patient Enrolled

42c572f80e7f468a59e9_carousel_image_86a4d0dd75515ed5d6e2_hospital.jpg
42c572f80e7f468a59e9_carousel_image_86a4d0dd75515ed5d6e2_hospital.jpg

Dr. Eric Whitman Leads Study of Experimental Drug That Uses Cold Virus to Disable Cancer Cells in Patients Who Have Not Responded to Other Treatments

Morristown, NJ Atlantic Health System Cancer Care is the first oncology institution in the world to sign on to, and to enroll the first patient in, a multicenter Phase IIa clinical trial of OBP-301 (Telomelysin®), a virus-based immunotherapy for late-stage melanoma that has not responded to other treatments. 

This leading-edge experimental therapy, which is under development by Japanese biotechnology company Oncolys BioPharma, uses the common cold virus to modify a gene that can selectively replicate in, and destroy, cancer cells. The study protocol was approved by the U.S. Food and Drug Administration (FDA) in June.

Sign Up for E-News

The clinical trial is being led locally by Eric D. Whitman, MD, FACS, medical director of Atlantic Health System Cancer Care and director of the Carol G. Simon Cancer Center’s Atlantic Melanoma Center at Morristown Medical Center and Overlook Medical Center.

“This targeted immunotherapy holds great promise for improving survival rates in patients with unresectable and metastatic melanoma,” said Dr. Whitman.  “We are proud to have been chosen as the first site for this leading edge clinical trial, and happy to be able to offer a wide range of the latest established and experimental treatments to our patients.”

Melanoma, the most serious form of skin cancer, affects more than 50,000 people each year. Although the chances of having melanoma increase with age, the number of cases among young adults is rising every year. Melanoma can have serious health consequences and may even be fatal.

The OBP-301 trial is a multicenter, Phase IIa study to evaluate how melanoma tumors respond to injection of this drug in patients with Stage III and Stage IV melanoma -- that is, to determine how much the drug shrinks or destroys tumors after it is injected into them.  The study, which will also look at potential side effects, is “open label,” meaning that all participants in the study will receive OBP-301. 

OBP-301 is a type of virus known as an adenovirus. Adenoviruses are common in nature and when they multiply in normal human cells they may cause infections that result in symptoms like those of the common cold or the flu.  OBP-301 has been genetically changed from the original virus to reproduce in target cancer cells that are emitting a certain signal. As a result of this reproduction, OBP-301 is believed to burst and kill tumor cells.

Study participants will receive multiple injections into their tumors over a period of several weeks.  Blood tests will be done to evaluate the level of virus in patients’ systems, and for immune response monitoring. Dr. Whitman and colleagues will also evaluate how long it takes to get a response and how long responses last, as well as overall survival and progression-free survival rates.

In preclinical studies, Oncolys demonstrated OBP-301’s anti-tumor activity in various types of cancer cells.  A Phase I clinical trial in the U.S. demonstrated the drug’s safety, and showed that it shrank tumors in a majority of study participants, who had a variety of solid tumors.  Additional studies of the drug have been completed, or are underway, in Japan, Korea and Taiwan.

The Atlantic Melanoma Center, a clinical and research center of excellence, is an internationally-recognized program. The center’s multidisciplinary approach-- combining the expertise of board-certified surgeons, medical oncologists, pathologists, radiation oncologists and nurses – treats all forms of melanoma, including those in the skin, mucous membranes and eyes.  Patients receive the latest medical treatments, and when needed, melanoma surgery is also available. 

For more information on the OBP-301 clinical trial or other studies, please call the Atlantic Melanoma Center at 973-971-7111.  

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Millburn/Short Hills

Video: Scoutmaster Ken Fineran Street Dedication Ceremony

May 21, 2018

MILLBURN, NJ - Millburn Township and Boy Scout Troop 17 of St. Rose of Lima honored the life and accomplishments of late Scoutmaster Kenneth W. Fineran on Sunday, May 20. Troop 17 Scouts, in conjunction with Millburn Township and St. Rose of Lima Church.

Vehicle Stolen from Residence; Millburn Police Department Investigating

May 10, 2018

On May 2, 2018 Millburn Police Officer Barbosa responded to Neiman Marcus on a theft report. Neiman Marcus personnel report a black male wearing a black jumpsuit with the word “Kappa” on the front, and a black male wearing a blue shirt with the word “Champion” on the front each took a backpack valued at $1195.00 each and left the store without making payment. The incident ...

AtlantiCast

AtlantiCast: Episode 15

On this week’s AtlantiCast, learn some important tips for controlling and avoiding diabetes from an Atlantic Health System expert, see how Atlantic Health is advancing cutting-edge research, hear what’s being done to keep health care environmentally friendly and much more!

 

Upcoming Millburn Township Committee Primary Election

May 12, 2018

Dear Fellow Millburn and Short Hills Residents,

Having given the selection of a candidate for the upcoming Millburn Township Committee primary election some serious thought, I have come to the conclusion that Corey Biller has the credentials to move the Township forward in a positive manner.

I know that Corey will bring a new and positive sensibility to the Committee, one that is ...

Upcoming Events

Carousel_image_0aa9371be0a5c11dde9e_32207734_590377658000828_3468436406508978176_n

Thu, May 24, 5:00 PM

The Hills Tavern, Millburn

Pre-Memorial Day Bash at Hills Tavern

Carousel_image_27a1c651521c971f9a4d_1cdb218c0a6934197fac_b2a4cff22151f502f44b2552724bef71_xl

Thu, May 24, 7:00 PM

Livingston Public Library, Livingston

Understanding Hearing Loss

Health & Wellness

Carousel_image_a672cdafc20b92829fd3_158ad19999d276c471a8_picture1

Fri, May 25, 12:30 PM

Millburn High School, Millburn

Fleet Week at Millburn High School

Carousel_image_5e04ad2ab20990a85225_da97f2a9df7ada16e603_best_crop_05ec05a6516f3f538bac_3a7a784dfab2e460085f_img_0033_2x

Wed, May 30, 6:15 PM

Millburn High School (Back grass fields), Millburn

Millburn Color Run

Arts & Entertainment Education Giving Back Other

Genius Gems Grand Opening in Millburn

May 22, 2018

Genius Gems LLC, a Unique STEM-based Learn & Play Space, Announces Grand Opening in Millburn, New Jersey on June 3rd  

 

What Can Your Child Build with over 24,000 Magnetic Tiles?

 

MILLBURN, NJ – Genius Gems, a STEM (Science, Technology, Engineering and Mathematics)-based learn and play space, is thrilled to announce the opening of ...

First Millburn Spring Festival Coming to Taylor Park

The Indian American Association of Millburn and Short Hills and The South Mountain Civic Association are organizing the 1st Millburn Spring Festival in Taylor park and Bauer Center on Sunday, June 10th, 2018 from 1-4 PM. The entire community is invited to a fun filled afternoon with many Millburn downtown restaurants setting up food stalls, Henna tattoo artist, Face painting and live Indian Music ...

Suicide Awareness and Intervention Training coming to Millburn Library May 23

Caring Contact, a crisis hotline that serves Northern and Central New Jersey, will host Suicide Awareness and Intervention Training at the Millburn Library on May 23, 6:30-8:30 p.m. There is no cost for this training but space is limited so registration is recommended.

 

To register, visit http://weblink.donorperfect.com/SuicideAwarenessSpring2018.

 

Caring contact's ...

SURVIVING A STROKE: Quick Medical Response Gives Mom Her Life Back

Carotid artery dissection. It’s one of the most common causes of stroke in younger adults.

And while you might not associate the word “stroke” with younger patients, the condition – if not treated immediately – could lead to paralysis and even death.

Lindsey Singh can attest to the importance of immediacy. The 31-year-old mother of two from Flanders experienced ...